BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial – Hagens ...
SAN FRANCISCO, Jan. 15, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and …